[Source: GenomeWeb News] – The Cancer Genome Atlas (TCGA) plans to completely characterize 200 samples from each of 10 tumor types over the next two years and 20 tumor types within five years, attendees at the American Association for Cancer Research annual meeting heard here yesterday.
As in the pilot stage of the project, Phase II of TCGA will involve sequence, SNP, and copy number analyses for each cancer type, as well as studies of expression, methylation, and small RNA profiles.
To achieve these goals, members of the consortium intend to exploit and expand on the standard operating procedures, infrastructure, and integrated analysis methods designed for the pilot phase of TCGA, National Cancer Institute Deputy Director Anna Barker explained during the session, which featured more than half a dozen TCGA representatives.
For more information: Researchers Outline Phase II of TCGA at AACR